Moonwalk Biosciences | LinkedIn (original) (raw)
Biotechnology Research
South San Francisco, California 3,850 followers
Pioneering precision epigenetic medicines.
About us
Moonwalk Biosciences is an early-stage therapeutics company co-founded by Dr. Feng Zhang and leading experts in cell state epigenetics including Alex Aravanis, the former CTO of Illumina. The company has developed a differentiated approach to mapping the epigenome of cellular states at the whole genome, single cell resolution level, as well as proprietary strategies for precise epigenetic engineering. The combination enables both a novel discovery platform and a path to developing therapeutics that include both epigenetic engineering and other traditional modalities.
Industry
Biotechnology Research
Company size
2-10 employees
Headquarters
South San Francisco, California
Type
Privately Held
Founded
2022
Locations
Employees at Moonwalk Biosciences
Updates
- Excited to announce that we will present new data using our #epigenetic technology at two upcoming scientific conferences, The Liver Meeting® 2024, hosted by the American Association for the Study of Liver Diseases (AASLD) and ObesityWeek® 2024, organized by The Obesity Society. Moonwalk will present new data highlighting its epigenetic capabilities in identifying new therapeutic targets for metabolic diseases and liver disorders using its proprietary EpiRead™ and EpiWrite™ platforms. Details of the presentations are as follows: ObesityWeek 2024 Oral Presentation Title: A Comprehensive Epigenetic Atlas of Human Adipocytes Date/Time: Monday, November 4, 9:15 - 9:30 AM Location: Room 207 The Liver Meeting 2024 Presentation Title: Elucidating Novel Therapeutic Targets for Metabolic Disease Through High Resolution Epigenetic Profiling of Primary Human Adipocytes Poster number: 1079 Date/Time: Friday, November 15, 1:00 - 2:00 PM Location: Hall C Read the full release: 👇👇https://lnkd.in/ej6g8rk3
Moonwalk Biosciences to Present New Epigenetic Data at ObesityWeek® 2024 and The Liver Meeting® 2024 businesswire.com - Our Chief Business Officer Elaine Cheung will be speaking on a panel tomorrow at BIO Investor Forum in SF! 🧬🧬 While the rate of IPOs this year is slightly increased versus 2023, the market is still much less active since 2021 and hoping the Q3 interest rate cut of 0.5% sparks additional investor support. This session will examine how private company CEOs should be preparing now for the types of IPOs that will be best received by the public markets, along with the implications for any opportunistic secondary offerings, amid an era of heightened geopolitical and market volatility. ModeratorJakob Dupont, MD MA, Executive Partner - Sofinnova Investments SpeakersEmily P. - MD, Principal - DCVC Bio Carolyn Ng - PhD, Partner and Managing Director - TPG Life Sciences InnovationsElaine Cheung, Chief Business Officer - Moonwalk Biosciences Pete Garcia, Chief Financial Officer - ALX Oncology Colin Walsh, PhD -Managing Director, Growth Equity, Goldman SachsView the agenda: 👇👇https://lnkd.in/dT3zhgkY
- Moonwalk Biosciences reposted this
“We're opening up the epigenome as a platform for drug discovery.” Moonwalk Biosciences is a biotech company devoted to pioneering precision epigenetic medicines. This week on Translating Aging, CEO & co-founder Alex Aravanis MD PhD tells us about Moonwalk’s mission to harness the power of epigenetics to develop a new class of medicines aimed at treating complex diseases and potentially extending human healthspan. Translating Aging is produced by BioAge Labs, a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases. Episode: https://lnkd.in/g6XtThZK(click ‘FOLLOW’ for links to your favorite podcast platform) Podcast: https://lnkd.in/gvF4X-ka - Looking forward to visiting Boston this week, and engaging with colleagues and potential partners!
Chief Business Officer
2mo
I'm excited to be speaking at the LSX World Congress USA, taking place on September 11-12 2024. Join me to access strategic knowledge and form new partnerships. https://lnkd.in/d2pPzx3g LSX USA Congress - We’re excited to welcome John Liles, Ph.D., VP Biology and Translational Science to the Moonwalk team and the formation of a world class Cardiometabolic Advisory Board. Dr. Liles brings deep experience as a drug discovery biologist with proven success advancing novel therapeutics from target discovery through IND for liver, kidney, lung and #cardiovascular diseases. “We are thrilled to welcome John to our team and announce the formation of our cardiometabolic advisory board,” said Alex Aravanis MD PhD, M.D., Ph.D., Co-founder & CEO, Moonwalk Biosciences, “John’s expertise in translating innovative therapeutics from discovery through IND will accelerate our ambitious R&D efforts.” Moonwalk will be presenting data and providing an update at future scientific meetings, including an oral presentation at ObesityWeek® 2024 and a poster presentation at American Association for the Study of Liver Diseases (AASLD) 2024. Read the release: https://lnkd.in/eQK6Uk6G
Moonwalk Biosciences Appoints VP of Biology and Translational Science and Announces Formation of Cardiometabolic Advisory Board businesswire.com
Join now to see what you are missing
Similar pages
- Montara Therapeutics, Inc. Biotechnology Research San Francisco, California
- Evercrisp Biosciences Biotechnology Research Berkeley, California
- Profluent Biotechnology Research Emeryville, CA
- Xaira Therapeutics Biotechnology Research Brisbane, CA
- CIONIC Biotechnology Research San Francisco, California
- Vilya Biotechnology Research South San Francisco, CA
- Kyverna Therapeutics Biotechnology Research Emeryville, California
- EditCo Bio Biotechnology Research Redwood City, California
- CARGO Therapeutics Biotechnology Research San Carlos, California
- Genesis Therapeutics Biotechnology Research Burlingame, California